One of the largest small molecule generic opportunities in the US for 2023 has arrived, with the advent of competition to Sanofi’s Aubagio (teriflunomide) tablets. Accord Healthcare and Sandoz are among firms confirming launch of their generic versions.
Launched just over a decade ago, Sanofi’s branded DHODH inhibitor is indicated to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?